SDGR vs RXRX
SDGR and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | SDGRSchrodinger, Inc. | RXRXRECURSION PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | — | $2.05B |
| P/S | — | 27.5x |
| Revenue | $259.04M(TTM) | — |
| Revenue growth (YoY) | 23.3% | 26.9% |
| Net income | -$54.34M(TTM) | — |
| Earnings growth (YoY) | 44.8% | -39.1% |
| EPS, diluted | $-0.73(TTM) | — |
| EBIT margin | -65.2% | -867.9% |
| ROE | -31.4% | -70.5% |
| ROIC | — | -175.2% |
| 1y total return | +47.6% | -22.2% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: SDGR vs RXRX
| 지표 | SDGR | RXRX |
|---|---|---|
| 최종 가치 | $3.7K | $1.2K |
| 총수익률 | -62.8% | -87.8% |
| CAGR | -16.6% | -32.1% |
| 변동성 | 63.8% | 92.6% |
| 샤프 | -0.04 | -0.02 |
| 소르티노 | -0.06 | -0.04 |
| 최대 낙폭 | -86.0% | -93.1% |
공통 거래일 1363일 기준, 2021-04-16 → 2026-09-18 · 무위험수익률 4.14% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)